Saad Kenderian, MD
Hematology · Rochester, MNNPI 1922284942
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,097 of the $12,345 with a category attached, or 89.9%. Gilead accounts for 66.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $8,129 and has fallen 61.7% since, to $3,114 in 2024.
Across 11 payments — averaging $1122.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$8K
- E.r. Squibb & Sons, L.L.C.$3K
- Novartis$983
Across 47 payments — averaging $60,423 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$2.2M
- Gilead$529K
- Morphosys AG$97K
- E.r. Squibb & Sons, L.L.C.$16K
- Jazz Pharmaceuticals Inc.$6K
What the payments were for
- Consulting fees$11,09790%
- Travel & lodging$9818%
- Food & beverage$2682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 9 | $8,249 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,114 |
| Novartis | 1 | $983 |
How this compares
$12,345 in reported general payments places this provider in the 75th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 33 | $411,690 |
| ImbruvicaIbrutinib | 23 | $289,892 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,636 |
| ValacyclovirValacyclovir Hcl | 15 | $706 |
| Acyclovir | 33 | $596 |
| Prednisone | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Shaji KumarRochester$452K
- Yi LinRochester$365K
- David DingliRochester$299K
- Morie GertzRochester$261K
- Grzegorz NowakowskiRochester$235K
- Sameer ParikhRochester$151K
- Lindsey RoekerRochester$106K
- Mark LitzowRochester$99K
- Angela DispenzieriRochester$87K
- Prashant KapoorRochester$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.